Jacobio Pharma Executes HK$0.46 Million Share Buyback, Reducing Free-Float by 0.009%

Bulletin Express05-08

Jacobio Pharmaceuticals Group Co., Ltd. (Jacobio Pharma) disclosed a repurchase of 72,300 ordinary shares on 8 May 2026 via the Hong Kong Stock Exchange. Shares were bought at prices ranging from HK$6.29 to HK$6.36, for a volume-weighted average repurchase price of HK$6.31 per share, bringing the total cash outlay to HK$0.46 million.

Following the transaction: • Issued shares outstanding (excluding treasury shares) fell from 784.997 million to 784.925 million, a 0.009% reduction. • Treasury shares rose from 6.76 million to 6.83 million. • Total issued shares remained unchanged at 791.76 million, as the repurchased stock is being held in treasury.

The buyback forms part of the mandate approved on 10 June 2025, which authorises Jacobio Pharma to repurchase up to 78.87 million shares. Cumulative repurchases under this mandate now stand at 3.81 million shares, equivalent to 0.48% of the company’s issued share count on the mandate date.

In line with Hong Kong listing rules, Jacobio Pharma is subject to a moratorium on issuing new shares or disposing of treasury shares until 7 June 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1168950001?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-08 18:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1168950001","market":"us","top_or_hot":-1,"title":"Jacobio Pharma Executes HK$0.46 Million Share Buyback, Reducing Free-Float by 0.009%","media":"Bulletin Express","content":"<p>Jacobio Pharmaceuticals Group Co., Ltd. (Jacobio Pharma) disclosed a repurchase of 72,300 ordinary shares on 8 May 2026 via the Hong Kong Stock Exchange. Shares were bought at prices ranging from HK$6.29 to HK$6.36, for a volume-weighted average repurchase price of HK$6.31 per share, bringing the total cash outlay to HK$0.46 million.</p>\n<p>Following the transaction:\n• Issued shares outstanding (excluding treasury shares) fell from 784.997 million to 784.925 million, a 0.009% reduction.  \n• Treasury shares rose from 6.76 million to 6.83 million.  \n• Total issued shares remained unchanged at 791.76 million, as the repurchased stock is being held in treasury.</p>\n<p>The buyback forms part of the mandate approved on 10 June 2025, which authorises Jacobio Pharma to repurchase up to 78.87 million shares. Cumulative repurchases under this mandate now stand at 3.81 million shares, equivalent to 0.48% of the company’s issued share count on the mandate date.</p>\n<p>In line with Hong Kong listing rules, Jacobio Pharma is subject to a moratorium on issuing new shares or disposing of treasury shares until 7 June 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Jacobio Pharma Executes HK$0.46 Million Share Buyback, Reducing Free-Float by 0.009%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJacobio Pharma Executes HK$0.46 Million Share Buyback, Reducing Free-Float by 0.009%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-05-08 18:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Jacobio Pharmaceuticals Group Co., Ltd. (Jacobio Pharma) disclosed a repurchase of 72,300 ordinary shares on 8 May 2026 via the Hong Kong Stock Exchange. Shares were bought at prices ranging from HK$6.29 to HK$6.36, for a volume-weighted average repurchase price of HK$6.31 per share, bringing the total cash outlay to HK$0.46 million.</p>\n<p>Following the transaction:\n• Issued shares outstanding (excluding treasury shares) fell from 784.997 million to 784.925 million, a 0.009% reduction.  \n• Treasury shares rose from 6.76 million to 6.83 million.  \n• Total issued shares remained unchanged at 791.76 million, as the repurchased stock is being held in treasury.</p>\n<p>The buyback forms part of the mandate approved on 10 June 2025, which authorises Jacobio Pharma to repurchase up to 78.87 million shares. Cumulative repurchases under this mandate now stand at 3.81 million shares, equivalent to 0.48% of the company’s issued share count on the mandate date.</p>\n<p>In line with Hong Kong listing rules, Jacobio Pharma is subject to a moratorium on issuing new shares or disposing of treasury shares until 7 June 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01167","symbol_name":"加科思-B","start_time":0,"source_url":"","article_id":"1168950001","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1168950001","pubTimestamp":1778235787,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Jacobio Pharmaceuticals Group Co., Ltd. (Jacobio Pharma) disclosed a repurchase of 72,300 ordinary shares on 8 May 2026 via the Hong Kong Stock Exchange. Shares were bought at prices ranging from...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01167":"加科思-B"},"translate_title":"雅可比奥制药执行46万港元股份回购，自由流通量减少0.009%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01167":1},"content_text":"Jacobio Pharmaceuticals Group Co., Ltd. (Jacobio Pharma) disclosed a repurchase of 72,300 ordinary shares on 8 May 2026 via the Hong Kong Stock Exchange. Shares were bought at prices ranging from HK$6.29 to HK$6.36, for a volume-weighted average repurchase price of HK$6.31 per share, bringing the total cash outlay to HK$0.46 million.\nFollowing the transaction:\n• Issued shares outstanding (excluding treasury shares) fell from 784.997 million to 784.925 million, a 0.009% reduction.  \n• Treasury shares rose from 6.76 million to 6.83 million.  \n• Total issued shares remained unchanged at 791.76 million, as the repurchased stock is being held in treasury.\nThe buyback forms part of the mandate approved on 10 June 2025, which authorises Jacobio Pharma to repurchase up to 78.87 million shares. Cumulative repurchases under this mandate now stand at 3.81 million shares, equivalent to 0.48% of the company’s issued share count on the mandate date.\nIn line with Hong Kong listing rules, Jacobio Pharma is subject to a moratorium on issuing new shares or disposing of treasury shares until 7 June 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1168950001","isCrawlerRequest":true}